During her tenure, Dr. Fouse held significant equity in Agios Pharmaceuticals. At one point, she had over 248,000 unexercised stock options, one of which was granted at an exercise price of $53.87 per share. This could mean a large potential...

During her tenure, Dr. Fouse held significant equity in Agios Pharmaceuticals. At one point, she had over 248,000 unexercised stock options, one of which was granted at an exercise price of $53.87 per share. This could mean a large potential payout if the company performed well. By the end of 2021, she had about 163,000 options remaining, reflecting her stakes in Agios as a drive for success. With stock options tied to the company’s future, these holdings show her commitment to Agios. When she officially left the position of CEO in August 2022, her unvested equity awards were set to continue vesting, keeping her financially engaged with the company's path forward. Her wealth in Agios not only tied her success to the company's but also aligned her interests with those of investors.